FINANCING GROWTH AND INNOVATION THROUGH NEW STOCK MARKETS: THE CASE OF EUROPEAN BIOTECHNOLOGY FIRMS

Fabio Bertoni and Pier Andrea Randone

A chapter in The Rise and Fall of Europe's New Stock Markets, 2004, pp 61-79 from Emerald Group Publishing Limited

Abstract: This chapter analyses how capital is raised and employed by a sample of 28 European biotechnology companies listed on Europe’s new stock markets from 1996 to 2000. We find that biotechnology companies rely heavily on IPO proceeds in order to finance their growth. We compare the behaviour of European firms to a sample of comparable U.S. firms. The analysis reveals that European companies tend to raise more capital at the IPO and to invest more aggressively in the short-run, whereas U.S. biotech firms tend to have more cash available before the IPO and invest more conservatively in the short-run.

Date: 2004
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.emerald.com/insight/content/doi/10.101 ... d&utm_campaign=repec (text/html)
https://www.emerald.com/insight/content/doi/10.101 ... d&utm_campaign=repec (application/pdf)
Access to full text is restricted to subscribers

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eme:afeczz:s1569-3732(04)10003-0

DOI: 10.1016/S1569-3732(04)10003-0

Access Statistics for this chapter

More chapters in Advances in Financial Economics from Emerald Group Publishing Limited
Bibliographic data for series maintained by Emerald Support ().